suppresSTEM Participants

In this highly integrated consortium, state of the art science and technologies will be applied by leading research driven companies and institutes to generate 1) a highly innovative bispecific antibody combination specifically targeting and inhibiting cancer stem cells in colorectal cancer ready to begin clinical testing and 2) a validated patient based drug screening and diagnostic tool. The suppresSTEM consortium consists of five suppresSTEM participants: Merus B.V. (The Netherlands), The Hubrecht Institute / The HUB foundation for organoid technology (The Netherlands), OcellO B.V. (The Netherlands), Institute for Research in Biomedicine (IRB Barcelona, Spain) and The Wellcome Trust Sanger Institute (UK).